BCYC News and Press, Bicycle Therapeutics plc From 05/12/23

Bicycle Therapeutics Plc (NASDAQ: BCYC) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 4.17% on the day to $23.97. Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicine...

Bicycle Therapeutics plc (NASDAQ: BCYC) and Orano Med, two biotechnology companies respectively, announce pre-clinical results. Bicycle is pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology and Orano Med is dev...

2023-05-10 07:51:51 ET Bayer ( OTCPK:BAYRY ) ( OTCPK:BAYZF ) and Bicycle Therapeutics ( NASDAQ: BCYC ) are collaborating to develop, make and sell Bicycle radioconjugates for multiple cancer targets. Bicycle will receive $45M upfront and potential development and ...

Collaboration will leverage Bicycle Therapeutic’s synthetic peptides for the discovery and development of multiple targeted radioconjugates of the company in oncology Advancing the use of bicycle peptides as a novel targeting approach in radiopharmaceuticals Bicycle Therapeutics to...

2023-05-04 10:12:18 ET Bicycle Therapeutics press release ( NASDAQ: BCYC ): Q1 GAAP EPS of -$1.30. Revenue of $4.89M (+26.7% Y/Y). For further details see: Bicycle Therapeutics GAAP EPS of -$1.30, revenue of $4.89M

- Continued progress across pipeline, including encouraging BT8009 Phase I dose escalation results presented in Q1’23 - Entered into a strategic collaboration with Novartis and expanded separate collaboration with the Division of Radiopharmaceutical Chemistry, German Cancer R...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that it has entered into a collaboration with the German Cancer Research Center (D...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that the company will present four poster presentations at the 2023 Ameri...

- Santiago Arroyo, M.D., Ph.D., appointed Chief Development Officer - Jennifer Perry, Pharm.D., promoted to Senior Vice President, Commercial Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its...

2023-03-28 07:27:49 ET Bicycle Therapeutics ( NASDAQ: BCYC ) signed an agreement with Novartis ( NYSE: NVS ) to develop and commercialize Bicycle radio-conjugates (BRCs) for multiple oncology targets. Under the agreement, Bicycle will get $50M upfront and is eligib...